β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1441-1446

  Nie, Wei ^a   Li, Bing ^a   Xiu, Qingyu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antibiotics; Lung infections; Mortality

Indexed keywords

BETA LACTAM; MACROLIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; COMMUNITY-ACQUIRED INFECTIONS; DRUG COMBINATION; PNEUMONIA; PUBLISHING; RISK;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; HUMANS; MACROLIDES; ODDS RATIO; PNEUMONIA; PUBLICATION BIAS; TREATMENT OUTCOME;

EID: 84903904746     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku033     Document Type: Review

References (33)

1. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Am J Emerg Med 2013; 31: 602-12.
2. Chinese Society of Respiratory Disease. Guidelines for the diagnosis and treatment of community acquired pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2006; 29: 651-5.
3. Lim WS, Baudouin S, George R et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: iii1-iii55.
4. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
5. Gleason PP, Meehan TP, Fine JM et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-72.
6. Dudas V, HopeflA, Jacobs R et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34: 446-52.
7. Houck PM, MacLehose RF, Niederman MS et al. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001; 119: 1420-6.
8. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-42.
9. Martinez JA, Horcajada JP, Almela M et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-95.
10. Garcia Vazquez E, Mensa J, Martinez JA et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent versus a β-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005; 24: 190-5.
11. Aspa J, Rajas O, Rodriguez de Castro F et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27: 1010-9.
12. Dwyer R, Ortqvist A, Aufwerber E et al. Addition of a macrolide to a β-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25: 518-21.
13. Metersky ML, Ma A, Houck PM et al. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131: 466-73.
14. Paul M, Nielsen AD, Gafter-Gvili A et al. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J 2007; 30: 525-31.
15. Rodríguez A, Mendia A, Sirvent J-M et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35: 1493-8.
16. Blasi F, Iori I, Bulfoni A et al. Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur Respir J 2008; 32: 902-10.
17. Bratzler DW, Ma A, Nsa W. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. Clin Infect Dis 2008; 47 Suppl 3: S193-201.
18. Tessmer A, Welte T, Martus P et al. Impact of intravenous β-lactam/macrolide versus β-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009; 63: 1025-33.
19. Naucler P, Darenberg J, Morfeldt E et al. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013; 68: 571-9.
20. Rodrigo C, McKeever TM, Woodhead M et al. Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 2013; 68: 493-5.
21. Asadi L, Sligl WI, Eurich DT et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012; 55: 371-80.
22. Wells G, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies inmeta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (9 January 2014, date last accessed).
23. Egger M, Smith GD, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
24. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull 1979; 86: 638-41.
25. Orwin R. A fail-safe N for effect size in meta-analysis. J Educ Stat 1983; 8: 157-9.
26. Plouffe JF, Breiman RF, Facklam RR et al. Bacteremia with Streptococcus pneumoniae. JAMA 1996; 275: 194-8.
27. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
28. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10-21.
29. Giamarellos-Bourboulis EJ, Pechè re JC, Routsi C et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008; 46: 1157-64.
30. Arnold FW, Summersgill JT, LaJoie AS et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175: 1086-93.
31. Meijvis S, van de Garde E, Rijkers G et al. Treatment with anti-inflammatory drugs in community-acquired pneumonia. J Intern Med 2012; 272: 25-35.
32. Leibovici L, Yahav D, Paul M. Systematic reviews and meta-analyses in infectious diseases: topics that merit special attention. Clin Microbiol Infect 2014; 20: 101-4.
33. Leibovici L, Soares-Weiser K, Paul M et al. Considering resistance in systematic reviews of antibiotic treatment. J Antimicrob Chemother 2003; 52: 564-71.